Eli Lilly bets big on India’s pharma future with $1 billion investment

US pharmaceutical giant Eli Lilly will invest more than $1 billion in India over the next few years to expand manufacturing capacity and shore up its global supply chain, the company said on Monday.

Rather than setting up wholly owned factories, Lilly will work with Indian contract drugmakers to build new production lines for its high-demand medicines and will establish a manufacturing and quality hub in Hyderabad to oversee these partnerships.

The Hyderabad hub will focus on providing technical oversight, harmonizing standards across sites, and supporting validation and release processes.

Demand for Lilly’s fastest-growing portfolio, especially GLP-1-based therapies for diabetes and obesity, has far outpaced global supply. The company’s decision to expand through collaborations in India instead of waiting for greenfield facilities to come online reflects an urgent need for scalable, cost-efficient manufacturing.

Lilly currently does not own any manufacturing facility in India, making this shift a major expansion of its network strategy. “We are making significant investments to increase manufacturing and medicine supply capacity around the world,” said Patrik Jonsson, president of Lilly International. He added that India would serve as “a hub for capability building within its global network.”

The India move complements Lilly’s broader manufacturing build-out, including about $27 billion in new US facilities, as it diversifies both geography and sourcing models to keep pace with surging worldwide demand for its weight-loss and diabetes drugs.

India is central to that strategy. Earlier this year, Lilly launched its once-weekly Mounjaro KwikPen in the country, extending its rivalry with Novo Nordisk in one of the world’s largest diabetes markets. Strong early demand since the drug’s debut in vial form this spring underscores why supply reliability and local availability have become as important as pricing in physician adoption and payer acceptance.

Making Hyderabad the coordination base for its partner sites is expected to reduce release lag, accelerate tech transfers, and tighten quality governance as production scales. The model also fits India’s evolving pharmaceutical profile: the country has moved far beyond generics and active ingredients to become a competitive center for biologics, sterile injectables, and device-drug combinations.

For India’s life-sciences ecosystem, Lilly’s investment is a major vote of confidence as it brings high-value jobs, new technical training opportunities, and spillover benefits for suppliers and logistics networks.

Analysts said the move demonstrates how multinational drugmakers are re-engineering supply networks to balance cost, compliance, and speed. For Lilly, success will depend on harmonizing Good Manufacturing Practices and analytics across multiple contract sites, a complex task given tightening global scrutiny of data integrity and supply allocation.